Crisantaspase Injection Exporter from India | Genliva Wellness LLP Leukemia Oncology Supplier

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP is a trusted Crisantaspase Injection Manufacturer in India producing advanced oncology formulations for hematological cancer treatment and specialized leukemia care.

Crisantaspase is widely prescribed for Acute Lymphoblastic Leukemia Treatment (ALL), particularly in patients who require an alternative asparaginase source. The formulation contains L-Asparaginase derived from Erwinia chrysanthemi, an enzyme that depletes circulating asparagine levels, helping inhibit the growth and survival of leukemia cells dependent on external asparagine supply.

The company also supplies these formulations as an Oncology Injectable Supplier and Leukemia Care Medicine Exporter for cancer hospitals, hematology centers, pediatric oncology departments, institutional procurement programs, and regulated international pharmaceutical markets.

Crisantaspase is formulated for leukemia and hematology oncology treatment.

Contains L-Asparaginase from Erwinia chrysanthemi
Enzyme-based anticancer formulation
Designed for acute lymphoblastic leukemia therapy
Helps deplete circulating asparagine levels

This formulation is prescribed in oncology and hematology treatment management.

Treatment of acute lymphoblastic leukemia (ALL)
Management of hematological malignancies
Used in combination chemotherapy protocols
Administered in pediatric oncology treatment plans
Utilized in leukemia management programs

Crisantaspase delivers targeted enzymatic support for leukemia treatment.

Helps reduce asparagine availability to leukemia cells
Supports acute lymphoblastic leukemia management
Useful in specialized hematology oncology protocols
Effective enzyme-based anticancer mechanism

Crisantaspase (L-Asparaginase from Erwinia chrysanthemi)

Crisantaspase (L-Asparaginase from Erwinia chrysanthemi)